With vaccines now authorized for children as young as six months, omicron boosters in development for the fall, and the nation’s first protein subunit vaccine for COVID-19 pending authorization, the U.S. appears to be well on its way to exiting the turmoil caused by the deadly SARS-CoV-2 virus. Globally, there is reason for optimism as well.
Clinical data readouts in 2022 have fallen by 14.8% in comparison with the same timeframe last year, and more than half of all reports are for drugs and biologics targeting three major therapeutic areas. In the first six months of the year, there have been 1,707 clinical entries, compared with 2,004 last year.
Analysts have warned that the medical device industry is not completely immune from any effects of a potential recession. With fears that a recession is looming, investment firm Needham said companies with capital equipment exposure could be the most vulnerable as hospitals look to repair equipment, instead of replacing it. During the 2008-2009 recession, sales in capital equipment declined for about 12 months, while procedure growth slowed for several years.